Beleodaq (Belinostat) Patent Expiration, LOE Window & CMS Spending
Beleodaq (Belinostat) by Aurobindo Pharma: FDA Orange Book core substance LOE 2026-08-10 (last listed 2027-10-27), 0 AB generics, $1.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Aurobindo Pharma |
| FDA Application & Pathway | N206256 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2026-08-10 |
| Last Listed Patent or Exclusivity Date | 2027-10-27 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.2M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $1.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 16.1% 2-yr change) |